As a trusted and established professional in the healthcare investment business, Jacob Gottlieb and his entrepreneurial prowess has led him to another financially business venture, expanding his success with Altium Capital. As a healthcare-centric investment business based in New York, Altium sets a clear focus on healthcare companies to grow its investment options. Mr. Gottlieb looks to healthcare investments that make helpful health treatment and medical treatment decisions.
Recently, Altium has made a few investments in healthcare companies such as Oramed Pharmaceuticals, Amarin Corporation and Oragenics.
As Altium’s primary investment, Oramed created an oral treatment insulin capsule and other oral capsules to help patients who have diabetes and hope to replace drugs taken through some sort of injection. The outstanding pharmaceutical expertise makes for great business and an even more medically sound team.
Amarin, another investment of Altium, has its main office in Dublin, Ireland and makes its work central to creating medicine to increase heart health. Amarin’s flagship drug, Vascepa, is a mix of fatty acid and lipid science and was greenlit for use in 2012.
The third investment Altium made with Oragenics was started in 1996 for the cause of antibiotics and preventing dangerous bacteria using good bacteria for the sake of therapy. Using special technology, Oragenics has been able to fight harmful bacteria and treat other diseases.
Even before Altium was realized, Jacob Gottlieb made his name in 2005 with a business venture called Visium Asset Management. In 2016, the hedge fund generated roughly $8 billion with an international base located in New York, San Francisco and London, respectively.
Prior to Visium Asset Management, he was a founder of Balyasny Asset Management and while he was there, he earned a lot of money and quickly grew his investment identity. After medicine, he transitioned to finances.
Find out more about Jacob Gottlieb: https://www.cnbc.com/jacob-gottlieb–cnbc/